New Ways to Stop HIV-1 from Growing
New Inhibitors Targeting HIV-1 Integrase During Viral Maturation
This research explores new compounds that could prevent the HIV virus from maturing and spreading in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern Mississippi NIH-funded |
| Lab location | 1 site (Hattiesburg, United States) |
| Project ID | NIH-11084939 on NIH RePORTER |
What this research studies
HIV-1 needs a special protein called integrase to make copies of itself and infect new cells. This project looks at a new type of compound, called ALLINIs, that might stop integrase from working correctly. These compounds appear to disrupt how the virus builds itself, leading to faulty virus particles that can't spread. We want to understand exactly how these compounds interfere with the virus's ability to mature and become infectious. Our goal is to design even better medicines that target this crucial step in the HIV life cycle.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to develop future treatments for individuals living with HIV/AIDS.
Not a fit: Patients without HIV/AIDS would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new anti-HIV medications that attack the virus in a different way, potentially helping patients who don't respond to current treatments.
How similar studies have performed: A new class of compounds has shown promise in disrupting HIV-1 integrase function in infected cells, suggesting this approach has potential.
Where this research is happening
Hattiesburg, United States
- University of Southern Mississippi — Hattiesburg, United States (Active)
Researchers
- Principal investigator: Kessl, Jacques J. — University of Southern Mississippi
- Study coordinator: Kessl, Jacques J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.